Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04724239	TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma	Phase Phase 2	Date Added 2021-01-26	Location China	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs chidamide, IBI305, Sintilimab	Tags MSS/ MMRp
NCT ID NCT03093116	TitleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase Phase 1, Phase 2	Date Added 2017-03-28	Location California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Belgium Canada China Denmark France Germany Hong Kong Hungary Italy Japan Korea, Republic of Netherlands Poland Singapore Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Oral repotrectinib (TPX-0005)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05677113	TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver	Phase Phase 2	Date Added 2023-01-10	Location Canada	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Placebo, QBECO	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Phase Phase 1	Date Added 2021-11-04	Location California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs NX-1607	Tags MSS/ MMRp
NCT ID NCT06218914	TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation	Phase Phase 1	Date Added 2024-01-23	Location California, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06792695	TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	Phase Phase 2	Date Added 2025-03-25	Location Arizona, United States California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New York, United States Ohio, United States Texas, United States Australia Canada China France Germany Italy Korea, Republic of Spain Taiwan United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT04008030	TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )	Phase Phase 3	Date Added 2019-07-05	Location California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin	Tags MSI-H/ MMRd
NCT ID NCT05328908	TitleA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2022-04-14	Location Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Tags MSS/ MMRp
NCT ID NCT04426669	TitleA Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering	Phase Phase 1, Phase 2	Date Added 2020-06-11	Location Minnesota, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT01351103	TitleA Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase Phase 1	Date Added 2011-05-10	Location California, United States Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canada France Germany Italy Netherlands Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs LGK974, PDR001	Tags MSS/ MMRp

Showing 251 to 260 of 299 entries